Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT06333899 2026-03-12

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Phase EARLY_PHASE1 Recruiting

15 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Phase 3 Recruiting

750 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

6,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT06378892 2024-04-23

ALK-PPL

Phase 2 Recruiting

45 enrolled

Thoracic

Non Small Cell Lung Cancer Metastatic

NCT06361589 2024-04-12

Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

Recruiting

200 enrolled

Thoracic

ALK-positive Non-small Cell Lung Cancer

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

1,550 enrolled

Tumor-Agnostic

Neoplasms

NCT06092086 2023-10-23

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Phase 2 Recruiting

126 enrolled

Thoracic

ALK Positive Non-small Cell Lung Cancer

Clinical Trials

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

PIKACHU

ATPase

EROS

ALK-PPL

Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

DRUP

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC